Delving into the Latest Updates on Laboratorios Gebro Pharma SA with Synapse

概览

关联

2

项与 Laboratorios Gebro Pharma SA 相关的临床试验

NCT04304053 / Completed临床3期IIT

Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)

This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).

开始日期2020-03-18

申办/合作机构

Laboratorios Rubió SA

[+3]

EUCTR2014-000906-36-ES / Not yet recruitingN/A

Randomized, parallel, multicenter, phase IV clinical trial to assess the efficacy of hyaluronic acid/chondroitin sulfate versus fosfomycin trometamol in recurrent urinary tract infection prevention. - INURE

开始日期2014-12-09

申办/合作机构

Laboratorios Gebro Pharma SA

100 项与 Laboratorios Gebro Pharma SA 相关的临床结果

登录后查看更多信息

0 项与 Laboratorios Gebro Pharma SA 相关的专利（医药）

登录后查看更多信息

7

项与 Laboratorios Gebro Pharma SA 相关的文献（医药）

2023-04-10·Cells

Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy.

Article

作者: Bedia, Carmen ; Pineda, Estela ; Pedrosa, Leire ; Martínez-Soler, Fina ; Stanzani, Elisabetta ; Tortosa, Avelina ; González Sánchez, José Juan ; Aldecoa, Iban ; Diao, Diouldé ; Sevilla, Ana ; Centellas, Marc ; Muñoz-Tudurí, Marta ; Mosteiro, Alejandra ; Ferrés, Abel ; Sierra, Àngels

BACKGROUNDThe high recurrence of glioblastoma (GB) that occurs adjacent to the resection cavity within two years of diagnosis urges an improvement of therapies oriented to GB local control. Photodynamic therapy (PDT) has been proposed to cleanse infiltrating tumor cells from parenchyma to ameliorate short long-term progression-free survival. We examined 5-aminolevulinic acid (5-ALA)-mediated PDT effects as therapeutical treatment and determined optimal conditions for PDT efficacy without causing phototoxic injury to the normal brain tissue.METHODSWe used a platform of Glioma Initiation Cells (GICs) infiltrating cerebral organoids with two different glioblastoma cells, GIC7 and PG88. We measured GICs-5-ALA uptake and PDT/5-ALA activity in dose-response curves and the efficacy of the treatment by measuring proliferative activity and apoptosis.RESULTS5-ALA (50 and 100 µg/mL) was applied, and the release of protoporphyrin IX (PpIX) fluorescence measures demonstrated that the emission of PpIX increases progressively until its stabilization at 24 h. Moreover, decreased proliferation and increased apoptosis corroborated the effect of 5-ALA/PDT on cancer cells without altering normal cells.CONCLUSIONSWe provide evidence about the effectiveness of PDT to treat high proliferative GB cells in a complex in vitro system, which combines normal and cancer cells and is a useful tool to standardize new strategic therapies.

2022-01-01·Reumatología Clínica

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

Article

作者: Tornero-Molina, Jesús ; Casamira, Núria ; de Agustín-de Oro, Juan José ; Hidalgo, Cristina ; Alperi-López, Mercedes ; Castellví, Ivan ; Calvo-Alén, Jaime ; González-Gay, Miguel Ángel ; Rubio, Esteban ; García-Vicuña, Rosario ; Sanmartí, Raimon ; Escudero, Alejandro

OBJECTIVEWe aimed to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease modifying drugs (DMARDs) in rheumatoid arthritis (RA).METHODSEleven experts on RA were selected. Two coordinators formulated 13 questions about the combination therapy of MTX with bDMARDs or tsDMARDs. A systematic review was conducted to answer the questions. Inclusion and exclusion criteria were established as well as the search strategies (Medline, Embase and the Cochrane Library were searched up to January 2019). Two reviewers selected the articles and collected data. Simultaneously, EULAR and ACR meeting abstracts were evaluated. Based on this evidence, the coordinators proposed preliminary recommendations that the experts discussed and voted in a nominal group meeting. The level of evidence and grade of recommendation was established using the Oxford Center for Evidence Based Medicine and the level of agreement with a Delphi. Agreement was established if at least 80% of the experts voted 'yes' (yes/no).RESULTSThe systematic review retrieved 513 citations of which 61 were finally included. A total of 10 recommendations were generated, voted and accepted. The level of agreement was very high in all of them and it was achieved in the first Delphi round. Final recommendations cover aspects such as the optimal MTX dosage, tapering strategy or patients' risk management.CONCLUSIONSThis document is intended to help clinicians solve usual clinical questions and facilitate decision making when treating RA patients with MTX in combination with bDMARDs or tsDMARDs.

2022-01-01·Reumatología Clínica (English Edition)

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

Review

作者: Castellví, Ivan ; Casamira, Núria ; de Agustín-de Oro, Juan José ; Hidalgo, Cristina ; Tornero-Molina, Jesús ; Alperi-López, Mercedes ; González-Gay, Miguel Ángel ; Calvo-Alén, Jaime ; Rubio, Esteban ; Sanmartí, Raimon ; García-Vicuña, Rosario ; Escudero, Alejandro

OBJECTIVEWe aimed to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease modifying drugs (DMARDs) in rheumatoid arthritis (RA).METHODSEleven experts on RA were selected. Two coordinators formulated 13 questions about the combination therapy of MTX with bDMARDs or tsDMARDs. A systematic review was conducted to answer the questions. Inclusion and exclusion criteria were established as well as the search strategies (Medline, Embase and the Cochrane Library were searched up to January 2019). Two reviewers selected the articles and collected data. Simultaneously, EULAR and ACR meeting abstracts were evaluated. Based on this evidence, the coordinators proposed preliminary recommendations that the experts discussed and voted in a nominal group meeting. The level of evidence and grade of recommendation was established using the Oxford Center for Evidence Based Medicine and the level of agreement with a Delphi. Agreement was established if at least 80% of the experts voted 'yes' (yes/no).RESULTSThe systematic review retrieved 513 citations of which 61 were finally included. A total of 10 recommendations were generated, voted and accepted. The level of agreement was very high in all of them and it was achieved in the first Delphi round. Final recommendations cover aspects such as the optimal MTX dosage, tapering strategy or patients' risk management.CONCLUSIONSThis document is intended to help clinicians solve usual clinical questions and facilitate decision making when treating RA patients with MTX in combination with bDMARDs or tsDMARDs.

100 项与 Laboratorios Gebro Pharma SA 相关的药物交易

登录后查看更多信息

100 项与 Laboratorios Gebro Pharma SA 相关的转化医学

登录后查看更多信息